216 related articles for article (PubMed ID: 17984836)
1. Rituximab removes intrarenal B cell clusters in patients with renal vascular allograft rejection.
Steinmetz OM; Lange-Hüsken F; Turner JE; Vernauer A; Helmchen U; Stahl RA; Thaiss F; Panzer U
Transplantation; 2007 Oct; 84(7):842-50. PubMed ID: 17984836
[TBL] [Abstract][Full Text] [Related]
2. Pharmacodynamics of rituximab in kidney transplantation.
Genberg H; Hansson A; Wernerson A; Wennberg L; Tydén G
Transplantation; 2007 Dec; 84(12 Suppl):S33-6. PubMed ID: 18162986
[TBL] [Abstract][Full Text] [Related]
3. B cells in cluster or in a scattered pattern do not correlate with clinical outcome of renal allograft rejection.
Scheepstra C; Bemelman FJ; van der Loos C; Rowshani AT; van Donselaar-Van der Pant KA; Idu MM; ten Berge IJ; Florquin S
Transplantation; 2008 Sep; 86(6):772-8. PubMed ID: 18813100
[TBL] [Abstract][Full Text] [Related]
4. B cell survival in intragraft tertiary lymphoid organs after rituximab therapy.
Thaunat O; Patey N; Gautreau C; Lechaton S; Fremeaux-Bacchi V; Dieu-Nosjean MC; Cassuto-Viguier E; Legendre C; Delahousse M; Lang P; Michel JB; Nicoletti A
Transplantation; 2008 Jun; 85(11):1648-53. PubMed ID: 18551073
[TBL] [Abstract][Full Text] [Related]
5. Refractory acute kidney transplant rejection with CD20 graft infiltrates and successful therapy with rituximab.
Alausa M; Almagro U; Siddiqi N; Zuiderweg R; Medipalli R; Hariharan S
Clin Transplant; 2005 Feb; 19(1):137-40. PubMed ID: 15659147
[TBL] [Abstract][Full Text] [Related]
6. Detection of B lymphocytes (CD20+) in renal allograft biopsy specimens.
Martins HL; Silva C; Martini D; Noronha IL
Transplant Proc; 2007 Mar; 39(2):432-4. PubMed ID: 17362749
[TBL] [Abstract][Full Text] [Related]
7. Anti-CD20 treatment depletes B-cells in blood and lymphatic tissue of cynomolgus monkeys.
Schröder C; Azimzadeh AM; Wu G; Price JO; Atkinson JB; Pierson RN
Transpl Immunol; 2003; 12(1):19-28. PubMed ID: 14551029
[TBL] [Abstract][Full Text] [Related]
8. Clinical impacts of CD38+ B cells on acute cellular rejection with CD20+ B cells in renal allograft.
Hwang HS; Song JH; Hyoung BJ; Lee SY; Jeon YJ; Kang SH; Chung BH; Choi BS; Choi YJ; Kim JI; Moon IS; Kim YS; Yang CW
Transplantation; 2010 Jun; 89(12):1489-95. PubMed ID: 20393401
[TBL] [Abstract][Full Text] [Related]
9. Immunohistochemical analysis as a means to predict responsiveness to rituximab treatment.
Teng YK; Levarht EW; Hashemi M; Bajema IM; Toes RE; Huizinga TW; van Laar JM
Arthritis Rheum; 2007 Dec; 56(12):3909-18. PubMed ID: 18050222
[TBL] [Abstract][Full Text] [Related]
10. Urinary CD20 mRNA as a surrogate of CD20-positive cells infiltration during allograft dysfunction in renal transplant patients.
Ponciano VC; Soares MF; Naka EL; Arruda EF; Cenedeze MA; Franco MF; Pacheco-Silva A; Câmara NO
Int Immunopharmacol; 2009 Jun; 9(6):663-7. PubMed ID: 19111631
[TBL] [Abstract][Full Text] [Related]
11. Treatment of plasma cell dyscrasias by antibody-mediated immunotherapy.
Treon SP; Shima Y; Preffer FI; Doss DS; Ellman L; Schlossman RL; Grossbard ML; Belch AR; Pilarski LM; Anderson KC
Semin Oncol; 1999 Oct; 26(5 Suppl 14):97-106. PubMed ID: 10561024
[TBL] [Abstract][Full Text] [Related]
12. Treatment of vascular rejection with rituximab in cardiac transplantation.
Garrett HE; Duvall-Seaman D; Helsley B; Groshart K
J Heart Lung Transplant; 2005 Sep; 24(9):1337-42. PubMed ID: 16143254
[TBL] [Abstract][Full Text] [Related]
13. Experiences and problems pre-operative anti-CD20 monoclonal antibody infusion therapy with splenectomy and plasma exchange for ABO-incompatible living-donor liver transplantation.
Usui M; Isaji S; Mizuno S; Sakurai H; Uemoto S
Clin Transplant; 2007; 21(1):24-31. PubMed ID: 17302588
[TBL] [Abstract][Full Text] [Related]
14. In vivo human B-cell subset recovery after in vivo depletion with rituximab, anti-human CD20 monoclonal antibody.
Sidner RA; Book BK; Agarwal A; Bearden CM; Vieira CA; Pescovitz MD
Hum Antibodies; 2004; 13(3):55-62. PubMed ID: 15598985
[TBL] [Abstract][Full Text] [Related]
15. Residual inflammation after rituximab treatment is associated with sustained synovial plasma cell infiltration and enhanced B cell repopulation.
Teng YK; Levarht EW; Toes RE; Huizinga TW; van Laar JM
Ann Rheum Dis; 2009 Jun; 68(6):1011-6. PubMed ID: 18647852
[TBL] [Abstract][Full Text] [Related]
16. Dense B cell infiltrates in paediatric renal transplant biopsies are predictive of allograft loss.
Muorah MR; Brogan PA; Sebire NJ; Trompeter RS; Marks SD
Pediatr Transplant; 2009 Mar; 13(2):217-22. PubMed ID: 18433412
[TBL] [Abstract][Full Text] [Related]
17. The emerging role of rituximab in organ transplantation.
Becker YT; Samaniego-Picota M; Sollinger HW
Transpl Int; 2006 Aug; 19(8):621-8. PubMed ID: 16827678
[TBL] [Abstract][Full Text] [Related]
18. Longterm clinical and immunological effects of anti-CD20 treatment in patients with refractory systemic lupus erythematosus.
Lindholm C; Börjesson-Asp K; Zendjanchi K; Sundqvist AC; Tarkowski A; Bokarewa M
J Rheumatol; 2008 May; 35(5):826-33. PubMed ID: 18398943
[TBL] [Abstract][Full Text] [Related]
19. Variability in the biological response to anti-CD20 B cell depletion in systemic lupus erythaematosus.
Albert D; Dunham J; Khan S; Stansberry J; Kolasinski S; Tsai D; Pullman-Mooar S; Barnack F; Striebich C; Looney RJ; Prak ET; Kimberly R; Zhang Y; Eisenberg R
Ann Rheum Dis; 2008 Dec; 67(12):1724-31. PubMed ID: 18250115
[TBL] [Abstract][Full Text] [Related]
20. Failure of anti-CD20 monoclonal antibody therapy to prevent antibody-mediated rejection in three crossmatch-positive renal transplant recipients.
Matignon M; Tagnaouti M; Audard V; Dahan K; Lang P; Grimbert P
Transplant Proc; 2007 Oct; 39(8):2565-7. PubMed ID: 17954175
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
